HA Blair - Drugs & Therapy Perspectives, 2023 - Springer
… ritonavir acting as a pharmacokinetic booster. In the phase II/III EPIC-HR trial, nirmatrelvir plus ritonavir reduced the risk of … -to-moderate COVID-19 athighrisk for progression to severe …
D Paraskevis, M Gkova, K Mellou… - The Journal of …, 2023 - academic.oup.com
… The analysis included all eligible recipients of molnupiravir and nirmatrelvir/ritonavir who … or nirmatrelvir/ritonavir reduced the risk of hospitalization and death in this highly vulnerable …
A Evans, C Qi, JO Adebayo, J Underwood, J Coulson… - Journal of Infection, 2023 - Elsevier
… A clinical access policy continues to support the treatment of higher-risk patients with … , and nirmatrelvir-ritonavir in preventing hospital admission and death in higher-risk patients (Fig. 1) …
G Tiseo, C Barbieri, V Galfo, S Occhineri… - Infectious Diseases and …, 2023 - Springer
… We found that patients treated with nirmatrelvir/ritonavir had a higher probability of having a negative test within 10 days from the first positive one. This data may be affected by some …
KM Souza, G Carrasco, R Rojas-Cortés… - Plos one, 2023 - journals.plos.org
… COVID-19 and eligible for nirmatrelvir-ritonavir treatment, a systematic review … nirmatrelvir-ritonavir. The objective of this study was to evaluate the performance of …
L Cegolon, R Pol, O Simonetti, F Larese Filon… - Pharmaceuticals, 2023 - mdpi.com
… reduce viral shedding time (VST) in high-risk SARS-CoV-2 patients, … Nirmatrelvir/Ritonavir in order to control VST in high-risk … on Nirmatrelvir/Ritonavir, the latter percentage increased to …
Y Mutoh, T Umemura, T Nishikawa, K Kondo, Y Nishina… - Viruses, 2023 - mdpi.com
Molnupiravir (MOV) and nirmatrelvir/ritonavir (NMV/r) are efficacious oral antiviral agents for patients with the 2019 coronavirus (COVID-19). However, little is known about their …
… coadministration of nirmatrelvir and ritonavir among vaccinated populations is uncertain. This study emulated a clinical trial to assess whether nirmatrelvir plus ritonavir reduces risk for …
B Zheng, J Tazare, L Nab, ACA Green… - The Lancet Regional …, 2023 - thelancet.com
… After adjusting for demographics, high-risk cohort categories, … in outcome risk between nirmatrelvir/ritonavir and sotrovimab … the risks of severe outcomes between nirmatrelvir/ritonavir …